Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RYTM
SELLRhythm Pharmaceuticals, Inc. · Healthcare · United States · $7.0B · Avg Vol: $93M/d
COMPANY DESCRIPTION
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of therapies for rare genetic diseases of obesity. Its flagship product, Imcivree (setmelanotide), is an FDA-approved MC4R agonist designed to restore weight control in patients with specific genetic mutations. The company holds a dominant niche position as a pioneer in precision medicine for melanocortin-4 receptor pathway disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.6M | 77.4M | 130.1M | 189.8M | 100.2% | 217.2M | 297.8M | — | 56.9% |
| EPS | -3.47 | -3.20 | -4.34 | -3.11 | — | -3.08 | -3.29 | -0.74 | — |
| Shares | 56.6M | 59.4M | 62.4M | 67.2M | +18.7% | 68.6M | — | — | — |
| Debt | 1.9M | 1.3M | 3.9M | 4.0M | 27.1% | — | — | — | — |
| Equity | 264.3M | 169.8M | 164.5M | 270.0M | 0.7% | — | — | — | — |
| Op CF | -173.4M | -136.2M | -113.9M | -115.7M | — | -119.5M | — | — | — |
| Inv CF | 28.0M | -5.7M | -48.2M | -137.2M | — | — | — | — | — |
| Fin CF | 213.8M | 74.4M | 191.2M | 218.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RYTM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc.(you) | $7.0B | 30 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
| PCVX | Vaxcyte, Inc. | $7.9B | 27 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 25 | SELL |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| CGON | CG Oncology, Inc. | $6.1B | 24 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%